Metformin for the Treatment of the Polycystic Ovary Syndrome
Abstract
A 23-year-old woman with the polycystic ovary syndrome presents for evaluation and possible treatment. She has a family history of diabetes, is obese, and has impaired glucose tolerance. Metformin therapy is recommended. Metformin increases insulin sensitivity and may reduce the risk of diabetes. In the polycystic ovary syndrome, long-term metformin treatment may increase ovulation, improve menstrual cyclicity, and reduce serum androgen levels.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.